Biogen Conference: Tau ASO CELIA Updates, Pre-Symptomatic Leqembi, SMA Phase 3 Plans [Yahoo! Finance]
Biogen Inc. (BIIB)
Last biogen inc. earnings: 4/22 07:12 am
Check Earnings Report
US:NASDAQ Investor Relations:
biogen.com/en_us/investors.html
Company Research
Source: Yahoo! Finance
lowering — phase 1b showed ~60% CSF tau knockdown and reductions on tau PET, with the trial focused on dose/safety rather than a single registrational p-value. AHEAD 3-45 / Leqembi: The AHEAD 3-45 program will evaluate lecanemab in pre-symptomatic patients (20–45 centiloids) using the PACC5 over four years, and Biogen says blood-based biomarkers cut confirmatory imaging screen-fail rates by ~50%, potentially enabling broader screening and earlier treatment. Salanersen & SMA phase 3 plans: Salanersen's phase 1b showed tolerability, rapid sustained neurofilament reductions and exploratory developmental gains in 24 participants, and Biogen has launched three phase 3 studies (STELLAR-1, STELLAR-2, SOLAR) aiming for once-yearly dosing and a path from high-dose Spinraza to salanersen if approved. Interested in Biogen Inc.? Here are five stocks we like better. 3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026 Biogen (NASDAQ:BIIB) executives highlighted progress across sev
Show less
Read more
Impact Snapshot
Event Time:
BIIB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIIB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIIB alerts
High impacting Biogen Inc. news events
Weekly update
A roundup of the hottest topics
BIIB
News
- Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026PR Newswire
- Securities Litigation on Behalf of Purchasers of Biogen, Inc. Securities (BIIB) Certified as Class ActionGlobeNewswire
- Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual MeetingGlobeNewswire
- Biogen (BIIB) had its price target raised by HSBC Holdings plc from $143.00 to $150.00.MarketBeat
- Biogen Details West Coast Hub, Felzartamab Phase 3 Plans and AMR Readout Timeline at Conference [Yahoo! Finance]Yahoo! Finance
BIIB
Earnings
- 2/9/26 - Beat
BIIB
Sec Filings
- 3/11/26 - Form 8-K
- 2/17/26 - Form 4
- 2/17/26 - Form 4
- BIIB's page on the SEC website